AAV9 제품 목록
Host Species
- Mouse（1）
Conjugate
- Unconjugated（1）
Reactive Species
- -（1）
Applications
- ELISA（1）
| 분자 | Cat. No. | Product Name | Host Species | Reactive Species | Applications | 규격 및 가격 |
|---|---|---|---|---|---|---|
| AAV9 | Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) |  Mouse | - | $400.00 100ug |
You Have Viewed 1-1 Of 1 Results
Asset Licensing Opportunity
Resources
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| TR-987 | Z-101; GLYC-101; MG-3601 | Phase 3 Clinical | Kazia Therapeutics | Varicose Veins; Wounds and Injuries; Varicose Ulcer | 상세 |
| Monovalent norovirus Vaccine (Vaxart) | VXA-G1-1-NN; VXA-G1.1-NN | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | 상세 |
| Poly ICLC (Oncovir) | Phase 2 Clinical | National Institutes Of Health, Oncovir Inc | Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Lymphoma, T-Cell; Glioma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Lymphoma, B-Cell; Osteosarcoma; Urinary Bladder Neoplasms; Mesothelioma; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Glioblastoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; HIV Infections | 상세 | |
| BO-112 | BO-112 | Phase 2 Clinical | Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Colorectal Neoplasms; Neurofibrosarcoma; Sarcoma; Sarcoma, Synovial; Liposarcoma; Leiomyosarcoma; Dermatofibrosarcoma; Stomach Neoplasms; Histiocytoma, Malignant Fibrous; Retroperitoneal Neoplasms; Esophageal Neoplasms; Carcinoma, Basal Cell; Fibrosarcoma; Rhabdomyosarcoma | 상세 | |
| Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS | VXA-NVV-201 | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | 상세 |
| CNTO-5 | CNTO-5 | Phase 1 Clinical | Inflammation | 상세 | |
| PGV-001 | PGV-001 | Phase 1 Clinical | Genentech Inc, Icahn School Of Medicine At Mount Sinai | Neoplasms; Urologic Neoplasms | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rintatolimod | AMP-516; AMP-518 | Approved | Hemispherx Biopharma Inc | Rintamod, Ampligen | Argentina | Fatigue Syndrome, Chronic | Hemispherx Biopharma Inc | 2017-01-01 | HIV Infections; Ovarian Neoplasms; Pancreatic Neoplasms; Mesothelioma; Influenza, Human; Post-Acute COVID-19 Syndrome; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fatigue Syndrome, Chronic; HIV Seropositivity; Breast Neoplasms, Male | 상세 |
Customer Reviews